Island Pharmaceuticals Ltd (ASX:ILA) has received approval to begin dosing its third and final cohort, in its single ascending dose (SAD) study for ISLA-101, a well-known drug candidate being repurposed for the prevention and treatment of dengue fever and other mosquito or vector borne diseases.
Following the dosing of the second cohort, the safety review committee concluded that the second cohort was safely dosed and the dosage was well-tolerated.
Island now expects screening of the third cohort to begin in January 2024, with final results on track for early in the year.
“Full steam ahead”
Island CEO Dr David Foster said: “This is very positive news to receive before the holiday period and we are now looking forward to moving full steam ahead with screening cohort three in early January.
“Today’s news brings us one step closer to finalising the ISLA-101 Single Ascending Dose Study and puts us in a strong position to move forward with our Phase 2a PEACH clinical trial.”
About the study
The single ascending dose study is a dose escalation study, in which three cohorts of healthy subjects will receive escalating doses of ISLA-101.
The study is designed to ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus.
Insights gained from this study will pave the way for optimising protocols for Island’s planned phase 2a PEACH clinical trial.